Bristol Myers Squibb (CELG-RI) EPS (Basic) (QoQ) (2009 - 2026)
Powered by 
Analysis
Bristol Myers Squibb (CELG-RI) EPS (Basic) (QoQ) (2009 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.41 Bn | 621.66 Bn | 17.26 Bn |
| 2 | AbbVie | 446.88 Bn | 440.31 Bn | 12.70 Bn |
| 3 | Merck | 357.90 Bn | 350.76 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.45 Bn | 259.76 Bn | 11.24 Bn |
| 5 | Pfizer | 156.64 Bn | 144.94 Bn | 10.94 Bn |
| 6 | Sanofi | 52.20 Bn | 44.82 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.90 Bn | 42.90 Bn | - |
| 8 | Incyte | 24.61 Bn | 20.08 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.57 Bn | 18.91 Bn | 683.80 Mn |
| 10 | Bristol Myers Squibb | 232.18 Mn | -10.83 Bn | 9.25 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 23.54% |
| Mar 31, 2026 | 146.20% |
| Dec 31, 2025 | -50.48% |
| Sep 30, 2025 | 67.09% |
| Jun 30, 2025 | -46.77% |
| Mar 31, 2025 | 3,133.09% |
| Dec 31, 2024 | -93.74% |
| Sep 30, 2024 | -27.89% |
| Jun 30, 2024 | 114.11% |
| Mar 31, 2024 | -791.19% |
| Dec 31, 2023 | -9.42% |
| Sep 30, 2023 | -5.26% |
| Jun 30, 2023 | -8.12% |
| Mar 31, 2023 | 13.60% |
| Dec 31, 2022 | 26.11% |
| Sep 30, 2022 | 12.53% |
| Jun 30, 2022 | 12.06% |
| Mar 31, 2022 | -44.02% |
| Dec 31, 2021 | 52.70% |
| Sep 30, 2021 | 46.80% |